Reversible Edema in a Male Patient Taking Parenteral Pantoprazole Infusion for Pyloric Stenosis

Sennaroğlu, Engın; Karakan, Şebnem; Kayataş, Mansur; Akdur, Saadet; Genc, Hulki; Karakan, Tarkan; Üçler, Rıfkı; Ürün, Yüksel

doi:10.1007/s10620-006-3095-1

Cited by 6 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although some cases of post pantoprazole administration anaphylaxis (22,23) and edema (24,25) have been reported in humans, these clinical signs were not observed in our population. While the aim of this study was not to evaluate the clinical safety of pantoprazole in calves, the lack of observed adverse effects correlate with previously reported pantoprazole use in ruminants for case management of cattle (4,26), camels (27), sheep (15,28), yaks (29), and goats (30,31).…”

Section: Discussioncontrasting

confidence: 72%

Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration

et al. 2020

View full text Add to dashboard Cite

Background: Neonatal calves are at risk of developing abomasal ulceration, but there is a lack of pharmacokinetic data for potential anti-ulcerative therapies, such as pantoprazole, in ruminant species.Objective: The study objectives were to estimate plasma pharmacokinetic parameters for pantoprazole in neonatal dairy calves after intravenous (IV) administration. A secondary objective was to quantify the concentrations of pantoprazole in edible tissues after IV dosing.Methods: Pantoprazole was administered to 9 neonatal Holstein calves at a dose of 1 mg/kg IV. Plasma samples were collected over 24 h and analyzed via HPLC-MS for determining pantoprazole concentrations. Pharmacokinetic parameters were derived via non-compartmental analysis. Tissue samples were collected at 1, 3, and 5 days after administration and analyzed via HPLC-MS.Results: Following IV administration, plasma clearance, elimination half-life, and volume of distribution of pantoprazole were estimated at 4.46 mL/kg/min, 2.81 h, and 0.301 L/kg, respectively. The global extraction ratio was estimated at 0.053 ± 0.015. No pantoprazole was detected in the edible tissues 1, 3, or 5 days after administration. A metabolite, pantoprazole sulfone was detected in all the edible tissues 1 and 3 days after administration.Conclusion: The reported plasma clearance for pantoprazole is less than that reported for alpacas but higher than reported in foals. The elimination half-life in calves appears to be longer than observed in foals and alpacas. While pantoprazole sulfone was detected in the tissues after IV administration, further research is needed as to the metabolism and potential tissue accumulation of other pantoprazole metabolites in calves. Future pharmacodynamic studies are necessary to determine the efficacy of pantoprazole on abomasal acid suppression in calves.

show abstract

Section: Discussioncontrasting

confidence: 72%

Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Other adverse effects of PPIs which may get overlooked, especially in the presence of other drugs, include reversible oedema [81,82], erectile dysfunction [83], lichenoid drug eruption [84], hepatitis [85], and interstitial nephritis [86]. Recently postulated and emerging conditions seen with long-term PPI use comprise Alzheimer's disease [87], Clostridium difficile infection [88,89], ageing of skin [90], restless legs syndrome-like symptoms [91], vitamin B12 deficiency [92], and decreased absorption of iron and vitamin C [93]; however, larger studies are needed to clarify this association and the clinical relevance.…”

Section: What Are the Risks Involved In Taking Ppis Indefinitely?mentioning

confidence: 99%

Proton pump inhibitors: use, misuse and concerns about long-term therapy

Rakesh

2011

Clin J Gastroenterol

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) are widely used in acid-related disorders of the stomach and oesophagus. Treatment with PPIs is usually extended indefinitely for maintaining symptom control, putting the patient at risk of adverse effects. On the other hand, there is also a tendency for physicians to prescribe these drugs unnecessarily for minor dyspepsia. The use of these best-selling drugs is expected to increase further as they are now available over-the-counter in many countries . Several newer PPIs are now available on the market with claims of superior therapeutic efficacy which are also excessively prescribed without considering their cost-effectiveness. This article examines why PPIs are now the leading antisecretory drugs, clinical aspects to be considered when prescribing newer PPIs, indications and recommended duration of treatment in each situation, over-prescription of PPIs, and adverse reactions that can emerge with long-term use.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2006

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Reversible Edema in a Male Patient Taking Parenteral Pantoprazole Infusion for Pyloric Stenosis

Cited by 6 publications

References 11 publications

Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration

Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration

Proton pump inhibitors: use, misuse and concerns about long-term therapy

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About